Close Menu

Breaking News

The effort is focused on building an atlas of immune cell types found across a range of Asian population groups as part of the Human Cell Atlas project.

The company will not be allowed to submit another plan for meeting the Nasdaq's listing requirements.

Last week, GenomeWeb's readers were most interested in the pain points labs are encountering in their coronavirus assay validations.

The consortium is developing a real-time PCR test for host detection assays targeting epigenetic signatures and viral RNA for early-stage monitoring of potentially infected individuals.

The firms have entered into a strategic partnership to integrate their respective amplicon-based target enrichment technologies for use in NGS testing.

As part of the placement, the Singapore-based firm has issued almost 17.9 million new ordinary shares at an issue price of $.175 per share. 

A pathologists' group has pointed out that the bill covers only EUA tests, and patients receiving tests with pending regulatory status may receive surprise bills.

In announcing a national emergency on Friday, Trump paraded out executives from the private sector as the administration tries to increase testing capacity

The test, authorized March 13, runs on the Applied Biosystems 7500 Fast Dx Real-Time PCR instrument and targets three regions of the SARS-CoV-2 genome.

According to the recall, initiated on Jan. 28, a glitch in the software’s data reporting to LIM systems could cause false-negative results from PCR assays running on the instrument.

The funds will support development of an assay on the DiaSorin Liason MDX sample-to-answer instrument.

Now valued at $5 billion, the company will apply the new funding to continue its expansion in diabetes, depression, and cardiology. 

PreCheck Health has an initial order of 30,000 tests and will register the product in Ecuador. The two firms have a similar distribution agreement covering Russia.

The agency will reimburse at about $35.91 per test for CDC assays and about $51.31 per test for non-CDC assays.

News items for the week of March 9, 2020.

BioReference is also now accepting specimens for testing SARS-CoV-2 and expects to offer 5,000 tests a day at satellite testing sites next week.

Under the NYSDOH's approach, labs need to provide validation data within 15 days of starting to test instead of having to pursue an EUA with the FDA.

The panel will aid in the diagnosis of patients with respiratory symptoms in about an hour by differentiating SARS-CoV-2 from other bacterial and viral pathogens.

The test is the third to receive EUA, following tests from the CDC and New York state, and it runs on Roche's Cobas 6800 and 8800 systems.

Under the 2018 agreement, the companies had planned to develop cell-free DNA assays for prenatal screening using Qiagen's GeneReader sequencing system.

BioMérieux had alleged infringement of two of its patents associated with nucleotide sequences to detect HIV-1 subtypes. 

Genes influencing NOTCH pathway activity were linked to head and neck squamous cell carcinoma with a mouse screen centered on genes with long tail mutations in human cases.

The genome mapping firm had fallen out of compliance with respect to its loan agreement with Innovatus and will prepay $5 million toward the loan principal.

Pages

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.